Literature DB >> 11308134

Localized and systemic scleroderma.

A Hawk1, J C English.   

Abstract

Scleroderma is a broad term encompassing both localized and systemic sclerosis. Localized scleroderma is a cutaneous limited fibrosis that manifests as plaque morphea, generalized morphea, linear scleroderma, and deep morphea. Systemic scleroderma (sclerosis) can manifest as either limited or diffuse disease. Limited systemic sclerosis is typically preceded by Raynaud's phenomenon, involves cutaneous sclerosis distal to the elbows, with gastrointestinal and pulmonary fibrosis, and anticentromere antibody positivity. Diffuse systemic scleroderma is characterized by simultaneous Raynaud's phenomenon, cutaneous skin involvement proximal to the elbow with gastrointestinal, pulmonary, renal and cardiac fibrosis, and positive serology for antitopoisomerase and anti-RNAP III antibodies. This article discusses the classification, epidemiology, pathogenesis, clinical manifestations, treatment, and prognosis of the scleroderma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11308134     DOI: 10.1053/sder.2001.23093

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  10 in total

1.  Mucocutaneous and demographic features of systemic sclerosis: a profile of 46 patients from eastern India.

Authors:  Sudip Kumar Ghosh; Debabrata Bandyopadhyay; Indranil Saha; Jayanta Kumar Barua
Journal:  Indian J Dermatol       Date:  2012-05       Impact factor: 1.494

2.  Hyaluronic Acid Filler Injection for Localized Scleroderma - Case Report and Review of Literature on Filler Injections for Localized Scleroderma.

Authors:  Jaishree Sharad
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-11

Review 3.  Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.

Authors:  Anna Kowalska-Kępczyńska
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

4.  Effects of a nonsurgical exercise program on the decreased mouth opening in patients with systemic scleroderma.

Authors:  G Pizzo; G A Scardina; P Messina
Journal:  Clin Oral Investig       Date:  2003-07-09       Impact factor: 3.573

Review 5.  Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.

Authors:  Michael Zeisberg; Raghu Kalluri
Journal:  Am J Physiol Cell Physiol       Date:  2012-12-19       Impact factor: 4.249

6.  The use of streptolysin o for the treatment of scars, adhesions and fibrosis: initial investigations using murine models of scleroderma.

Authors:  Stephen W Mamber; Vit Long; Ryan G Rhodes; Sunthorn Pond-Tor; Lyn R Wheeler; Kellie Fredericks; Brian Vanscoy; Jean-Frederic Sauniere; Remy Steinschneider; Jean-Claude Laurent; John McMichael
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-04

7.  Interventions for morphea.

Authors:  Julia V de Albuquerque; Brenda Ng Andriolo; Monica Ra Vasconcellos; Vinicius T Civile; Anne Lyddiatt; Virginia Fm Trevisani
Journal:  Cochrane Database Syst Rev       Date:  2019-07-16

8.  Limited mouth opening secondary to diffuse systemic sclerosis.

Authors:  Tomoko Wada; Saravanan Ram
Journal:  Case Rep Dent       Date:  2013-12-18

9.  Endothelin-1 in systemic sclerosis.

Authors:  Mehrdad Aghaei; Farhad Gharibdost; Habib Zayeni; Maryam Akhlaghi; Sima Sedighi; Abduo Rahman Rostamian; Naser Aghdami; Mahdieh Shojaa
Journal:  Indian Dermatol Online J       Date:  2012-01

10.  Characterization and Treatment of Unilateral Facial Muscle Spasm in Linear Scleroderma: A Case Report.

Authors:  Fabio Danisi; Emma Guidi
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-01-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.